A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

NCT07103018 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

144

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration-resistant Prostate Cancer
Metastatic Castration-Resistant Prostate Cancer Patients
Metastatic Castration-resistant Prostate Cancer, mCRPC
mCRPC
mCRPC (Metastatic Castration-resistant Prostate Cancer)

Interventions

DRUG: KTX-2001
DRUG: KTX-2001 + Darolutamide (NUBEQA®)

Sponsor

K36 Therapeutics, Inc.